Combination of Allergen-Specific Immunotherapy With Biologics in Severe Asthma: Counterintuitive or Rational?

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F25%3A10500734" target="_blank" >RIV/00216208:11110/25:10500734 - isvavai.cz</a>

Result on the web

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=No5HC0pgsd" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=No5HC0pgsd</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.jaip.2025.05.003" target="_blank" >10.1016/j.jaip.2025.05.003</a>

Result language

angličtina

Original language name

Combination of Allergen-Specific Immunotherapy With Biologics in Severe Asthma: Counterintuitive or Rational?

Original language description

Although numbers vary, most patients with severe asthma have eosinophilic asthma. Many of them have the allergic asthma endotype, particularly those with concomitant allergic rhinitis (AR). Allergen immunotherapy (AIT) is the only disease-modifying therapy offering long-term effectiveness for allergic respiratory disorders, including asthma, but it is contraindicated in patients with uncontrolled disease. Patients with severe asthma often have frequent exacerbations, making them poor candidates for AIT. However, after approximately 6 to 12 months on biologic therapy, many patients become exacerbation-free and obtain good symptom control and even improved lung function. Thus, in these patients, add-on AIT, subcutaneous or sublingual, is possible. Importantly, AIT could contribute to achieving clinical remission in severe asthma with biologic therapy, that even may be sustained after cessation of treatment. In a few landmark trials of AIT added to biologics (omalizumab, dupilumab, or tezepelumab), mechanisms were also studied, unveiling the additional benefit of these combinations in enhancing not only safety and tolerability, but possibly also efficacy. We present a summary of clinical trials combining immunotherapy with aeroallergens with biologic therapy in patients with respiratory allergy and discuss the cons and pros of AIT in patients with severe allergic asthma who received biological therapy, concluding that this combination could benefit many of these patients.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30102 - Immunology

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2025

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

The Journal of Allergy and Clinical Immunology: In Practice

ISSN

2213-2198

e-ISSN

2213-2201

Volume of the periodical

13

Issue of the periodical within the volume

7

Country of publishing house

NL - THE KINGDOM OF THE NETHERLANDS

Number of pages

16

Pages from-to

1581-1596

UT code for WoS article

001533831000010

EID of the result in the Scopus database

2-s2.0-105007731706